<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01352910</url>
  </required_header>
  <id_info>
    <org_study_id>2010/082/HP</org_study_id>
    <nct_id>NCT01352910</nct_id>
  </id_info>
  <brief_title>rTMS and Functional Paralysis</brief_title>
  <acronym>PARALYSTIM</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psychogenic paralysis presents a real treatment challenge. Despite psychotherapy,&#xD;
      physiotherapy, antidepressants, acupuncture or hypnosis, the outcome is not always&#xD;
      satisfactory with persistent symptoms after long-term follow-up. In a preliminary&#xD;
      retrospective study on 70 patients with psychogenic paralysis (44F/26M, mean age : 24.7 Â±&#xD;
      16.6 ys), repetitive transcranial magnetic stimulation (rTMS) delivered over the motor cortex&#xD;
      at low frequency was effective in 89% of cases (recovery: n=53, improvement: n=9), with an&#xD;
      immediate or quasi-immediate recovery in 73% of patients (n=51).&#xD;
&#xD;
      We suggest that the dramatic improvement of psychogenic paralysis after rTMS could be due to&#xD;
      the restoration of an appropriate cerebral connectivity by activating a suppressed motor&#xD;
      cortex. Nevertheless, the possibility of a placebo effect cannot be ruled out.&#xD;
&#xD;
      A prospective multicentric (Rouen, Caen) randomized controlled trial versus placebo will be&#xD;
      done for 94 patients with psychogenic paralysis, 1- to evaluate rTMS efficacy for paralysis&#xD;
      at short and long term follow-up, and 2- to confirm rTMS safety. Two rTMS sessions will be&#xD;
      performed at D0 and D1 (120 pulses over 2 days, delivered over the motor cortex at 2 Hz) with&#xD;
      an active or a sham coil. Post-rTMS assessment will evaluate 1- the degree of the paralysis&#xD;
      at D2 (quantified by a videotape) and D60 (quantified by an interview and a standardized&#xD;
      examination), 2- the number and gravity of side effects.&#xD;
&#xD;
      If psychogenic paralysis improvement by motor cortex rTMS is confirmed, rTMS could be&#xD;
      considered a useful early therapeutic option.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of paralysis at D2, quantified by a videotape made at D2 and interpreted by to independent examinators</measure>
    <time_frame>D2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of side effects occurred during the 2 days of rTMS, between D0 and D1</measure>
    <time_frame>D0, D1, D2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of side effects gravity occurred during the 2 days of rTMS, between D0 and D1</measure>
    <time_frame>D0, D1 and D2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of paralysis at D60, quantified by an interview and a standardized examination</measure>
    <time_frame>D60</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Psychogenic Paralysis</condition>
  <arm_group>
    <arm_group_label>effective rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rTMS</intervention_name>
    <description>120 pulses 0.2 Hz</description>
    <arm_group_label>effective rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham rTMS</intervention_name>
    <description>120 pulses 0.2 Hz</description>
    <arm_group_label>Sham rTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 14 years old&#xD;
&#xD;
          -  Psychogenic paralysis according to the DSM-IV-R&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contra-indication of rTMS&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Previous history of epilepsia&#xD;
&#xD;
          -  Previous session of rTMS (for any indication)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Chastan, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rouen University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>May 11, 2011</study_first_submitted>
  <study_first_submitted_qc>May 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2011</study_first_posted>
  <last_update_submitted>August 16, 2016</last_update_submitted>
  <last_update_submitted_qc>August 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

